Last year, Journey Medical Corp generated 25.01M USD for its biggest-performing segment, Qbrexa. The United States made the largest contribution, accounting for 61.86M USD last year. For the latest quarter, Journey Medical Corp reported the revenue of 17.96M USD for the period ending 2026-06-30, which came from the top-performing segment, Eurax. United States contributed the highest revenue, at 18.51M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Qbrexa

Emrosi

Accutane

Amzeeq

Other branded revenue

Other legacy

Zilxi

Targadox

Exelderm

Ximino

FY2025

FY2024

FY2023

FY2022

FY2021

Qbrexa

25.01M(40.85%)

25.11M(45.55%)

25.41M(38.74%)

26.71M(37.63%)

17.06M(27.02%)

Emrosi

14.74M(24.08%)

--(--)

Accutane

12.88M(21.04%)

19.41M(35.20%)

20.17M(30.75%)

18.37M(25.88%)

10.05M(15.92%)

Amzeeq

5.86M(9.57%)

5.01M(9.09%)

6.20M(9.46%)

7.24M(10.20%)

--(--)

Other branded revenue

2.74M(4.47%)

--(--)

35.00K(0.05%)

--(--)

37.00K(0.06%)

Other legacy

--(--)

3.96M(7.18%)

5.92M(9.03%)

--(--)

Zilxi

--(--)

1.64M(2.98%)

1.96M(2.99%)

2.27M(3.20%)

--(--)

Targadox

--(--)

3.20M(4.89%)

7.97M(11.23%)

22.38M(35.45%)

Exelderm

--(--)

2.40M(3.65%)

3.46M(4.88%)

5.36M(8.49%)

Ximino

--(--)

287.00K(0.44%)

4.96M(6.98%)

8.25M(13.06%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

FY2025

FY2024

FY2023

FY2022

FY2021

United States

61.86M(100.00%)

56.13M(100.00%)

79.18M(100.00%)

73.67M(100.00%)

--(--)